Access cutting-edge esophageal cancer treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.
Access esophageal cancer specialists in New York at no cost
This study follows strict safety protocols and ethical guidelines
All study-related esophageal cancer treatment provided free
This is a Phase 1/2, multicenter, randomized, open-label umbrella platform study to evaluate the safety and efficacy of investigational agents with or without pembrolizumab and/or chemotherapy, for the treatment of participants with second line (2L) esophageal squamous cell carcinoma (ESCC) who have previously been exposed to PD-1/PD-L1 based treatment.
Sponsor: Merck Sharp & Dohme LLC
Check if you qualify for this esophageal cancer clinical trial in New York, NY
If you're searching for esophageal cancer treatment options in New York, NY, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced esophageal cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.